Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease Poster Simulations to Inform Dose Selection for a Phase 2b Trial Investigating TOUR006, a Fully Human Anti-IL6 Antibody, for Treatment of Thyroid Eye Disease CertaraFebruary 7, 2025
Machine Learning for Population PK Model Selection: Theory and Practice On-Demand Webinar Machine Learning for Population PK Model Selection: Theory and Practice Three of Certara's expert modelers provide a gentle introduction to machine learning in our field.…CertaraFebruary 7, 2025
Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling On-Demand Webinar Simcyp Version 24: Advancing PBPK capabilities and translating new science and technology into regulatory-accepted predictive modeling With the release of Version 24, the Simcyp Simulator introduces cutting-edge enhancements that further elevate…CertaraFebruary 7, 2025
Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies Publication Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies This study conducted a population pharmacokinetic (PK) and pharmacodynamic (PD) analysis of navtemadlin, an MDM2…CertaraFebruary 6, 2025
Understanding Variability in CAR-T Cell Therapy Kinetics Publication Understanding Variability in CAR-T Cell Therapy Kinetics Axicabtagene ciloleucel (axi-cel), a CAR-T cell therapy for relapsed and refractory non-Hodgkin’s lymphoma (NHL), demonstrates…CertaraJanuary 23, 2025
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) On-Demand Webinar Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive…CertaraJanuary 9, 2025
Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA Poster Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA CertaraDecember 11, 2024
Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development Video Piet van der Graaf on AI and AI-assisted approaches in drug discovery & development At the 2024 AAPS PharmSci 360 conference, Bioanalysis Zone interviewed Piet van der Graaf, Senior…CertaraDecember 10, 2024
Advancing pharmacometrics in Africa – Transition from capacity development toward job creation Publication Advancing pharmacometrics in Africa – Transition from capacity development toward job creation This CPT article showcases, the Applied Pharmacometrics Training (APT) program, launched in 2021 by Pharmacometrics…CertaraDecember 9, 2024
Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Treatment of Patients with Severe Hypertriglyceridemi CertaraNovember 22, 2024